IL-6 biology: implications for clinical targeting in rheumatic disease
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IL-6 biology: implications for clinical targeting in rheumatic disease
Authors
Keywords
-
Journal
Nature Reviews Rheumatology
Volume 10, Issue 12, Pages 720-727
Publisher
Springer Nature
Online
2014-08-19
DOI
10.1038/nrrheum.2014.127
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cutting Edge: Soluble IL-6R Is Produced by IL-6R Ectodomain Shedding in Activated CD4 T Cells
- (2014) E. M. Briso et al. JOURNAL OF IMMUNOLOGY
- Therapeutic Targeting of IL-6 Trans Signaling Counteracts STAT3 Control of Experimental Inflammatory Arthritis
- (2014) M. A. Nowell et al. JOURNAL OF IMMUNOLOGY
- Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table 1
- (2013) Daniel E Furst et al. ANNALS OF THE RHEUMATIC DISEASES
- Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
- (2013) Joachim Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial
- (2013) Tom W J Huizinga et al. ANNALS OF THE RHEUMATIC DISEASES
- Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature
- (2013) Archana Jain et al. Immunotherapy
- IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality
- (2013) Hong Zhang et al. JOURNAL OF CLINICAL INVESTIGATION
- Trp53 Deficiency Protects against Acute Intestinal Inflammation
- (2013) M. E. Spehlmann et al. JOURNAL OF IMMUNOLOGY
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Immune mechanisms in medium and large-vessel vasculitis
- (2013) Cornelia M. Weyand et al. Nature Reviews Rheumatology
- Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm
- (2013) Jamie Robertson et al. Nature Reviews Rheumatology
- Tocilizumab in rheumatoid arthritis: A meta-analysis of efficacy and selected clinical conundrums
- (2013) Geraldine Navarro et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Interleukin-6: From basic biology to selective blockade of pro-inflammatory activities
- (2013) Jürgen Scheller et al. SEMINARS IN IMMUNOLOGY
- Functional IL6R 358Ala Allele Impairs Classical IL-6 Receptor Signaling and Influences Risk of Diverse Inflammatory Diseases
- (2013) Ricardo C. Ferreira et al. PLoS Genetics
- Interleukin-6 Receptor Blockade Enhances CD39+ Regulatory T Cell Development in Rheumatoid Arthritis and in Experimental Arthritis
- (2013) A. Thiolat et al. Arthritis & Rheumatology
- Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement
- (2012) Monika M Schoels et al. ANNALS OF THE RHEUMATIC DISEASES
- Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
- (2012) Josef S Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab in the treatment of the adult-onset Still's disease: current clinical evidence
- (2012) Hubert de Boysson et al. CLINICAL RHEUMATOLOGY
- Hitting a complex target: an update on interleukin-6 trans-signalling
- (2012) Georg H Waetzig et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease
- (2012) John J. O'Shea et al. IMMUNITY
- Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis
- (2012) Jan Sodenkamp et al. IMMUNOBIOLOGY
- IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
- (2012) Stefan Rose-John International Journal of Biological Sciences
- IL-6 Controls the Innate Immune Response against Listeria monocytogenes via Classical IL-6 Signaling
- (2012) J. Hoge et al. JOURNAL OF IMMUNOLOGY
- The interleukin 6 pathway and atherosclerosis
- (2012) Jürgen Scheller et al. LANCET
- Inflammatory bone loss: pathogenesis and therapeutic intervention
- (2012) Kurt Redlich et al. NATURE REVIEWS DRUG DISCOVERY
- Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica
- (2012) S. Unizony et al. ARTHRITIS CARE & RESEARCH
- Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica
- (2012) Bernd C. Kieseier et al. JAMA Neurology
- Therapeutic Targeting of the Interleukin-6 Receptor
- (2011) Toshio Tanaka et al. Annual Review of Pharmacology and Toxicology
- The pro- and anti-inflammatory properties of the cytokine interleukin-6
- (2011) Jürgen Scheller et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model*
- (2011) Tanja Barkhausen et al. CRITICAL CARE MEDICINE
- The value of blocking IL-6 outside of rheumatoid arthritis: current perspective
- (2011) Miho Murakami et al. CURRENT OPINION IN RHEUMATOLOGY
- Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
- (2011) Simon A. Jones et al. JOURNAL OF CLINICAL INVESTIGATION
- Tocilizumab: a novel therapy for patients with large-vessel vasculitis
- (2011) C. Salvarani et al. RHEUMATOLOGY
- ADAM17: a molecular switch to control inflammation and tissue regeneration
- (2011) Jürgen Scheller et al. TRENDS IN IMMUNOLOGY
- Integrated safety in tocilizumab clinical trials
- (2011) Michael H Schiff et al. ARTHRITIS RESEARCH & THERAPY
- Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives
- (2010) G. D. Kitas et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
- (2010) Gabor G. Illei et al. ARTHRITIS AND RHEUMATISM
- Is Interleukin-6 Receptor Blockade the Holy Grail for Inflammatory Diseases?
- (2010) M A Febbraio et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Interleukin-6 as a Therapeutic Target in Candidate Inflammatory Diseases
- (2010) N Nishimoto CLINICAL PHARMACOLOGY & THERAPEUTICS
- Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice
- (2010) Athena Chalaris et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica
- (2010) K. HAGIHARA et al. JOURNAL OF RHEUMATOLOGY
- Effects of Inhibition of Interleukin-6 Signalling on Insulin Sensitivity and Lipoprotein (A) Levels in Human Subjects with Rheumatoid Diseases
- (2010) Olaf Schultz et al. PLoS One
- The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab
- (2010) Y. Shima et al. RHEUMATOLOGY
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated Cancer
- (2009) Sergei Grivennikov et al. CANCER CELL
- Essential Roles of IL-6 Trans-Signaling in Colonic Epithelial Cells, Induced by the IL-6/Soluble-IL-6 Receptor Derived from Lamina Propria Macrophages, on the Development of Colitis-Associated Premalignant Cancer in a Murine Model
- (2009) S. Matsumoto et al. JOURNAL OF IMMUNOLOGY
- Heterogeneity of human effector CD4+ T cells
- (2009) Francesco Annunziato et al. ARTHRITIS RESEARCH & THERAPY
- IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells
- (2008) T. Korn et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now